Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 778 across all filing types
Latest filing 2017-03-20 Regulatory Filings
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a short press release dated March 20, 2017, announcing that Mauna Kea Technologies reaffirms its eligibility for the PEA-PME investment scheme (a French tax-advantaged investment account for SMEs). This announcement relates to the company's structure and its attractiveness to certain investors, but it does not fit neatly into standard SEC filings like 10-K, ER, or IR. It is not a dividend announcement (DIV), management change (MANG), or director dealing (DIRS). Since it is a specific, non-standard regulatory/financial status update that doesn't match the other specific categories (like CAP for financing or SHA for share structure changes), the most appropriate classification is the general 'Regulatory Filings' fallback category (RNS), as it is an official public announcement regarding compliance/status.
2017-03-20 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 99% confidence The document is a press release dated March 13, 2017, announcing the appointment of Dr. Jennifer F. Tseng to the Board of Directors. This type of announcement, detailing changes in senior personnel or the board, directly corresponds to the definition of 'Board/Management Information'. The filing code for this is MANG.
2017-03-13 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release dated March 13, 2017, announcing the appointment of Dr. Jennifer F. Tseng to the Board of Directors of Mauna Kea Technologies. This type of announcement, detailing changes in the company's board or senior management, directly corresponds to the definition of 'Board/Management Information'. The filing code for this category is MANG.
2017-03-13 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated March 2, 2017, announcing that a peer-reviewed publication highlighted the superiority of the company's product (Cellvizio) for diagnosing gastric cancer. It details key findings (sensitivity, specificity, biopsy reduction) from the meta-analysis within the publication. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about external validation/research findings related to the company's technology, which fits best under a general regulatory announcement or news release category. Since it is a specific announcement of news/results that doesn't fit the other specific categories (like DIV, CAP, MANG, etc.), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for significant, non-standard announcements.
2017-03-02 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Environmental & Social Information Classification · 99% confidence The document is a press release dated March 2, 2017, announcing the publication of a review/meta-analysis in the British Medical Journal Open Gastroenterology regarding the superiority of endomicroscopy (Cellvizio) in diagnosing stomach cancer. The text focuses on communicating positive clinical results and market potential, typical of an announcement intended for investors and the public. It is not a full financial report (10-K or IR), a transcript (CT), or a formal regulatory filing like a proxy statement. Since it is an announcement about positive clinical/research findings that impacts the company's value proposition, it aligns best with a general corporate announcement. Given the options, and since it is not explicitly an Earnings Release (ER) or a specific financial/governance document, it falls under the general category for corporate news releases. However, because it is a specific announcement of a publication that supports the company's technology, it is most accurately classified as a general Regulatory Filing (RNS) if no better fit exists, or potentially an Investor Presentation (IP) if it were a slide deck, but here it is a news release about external validation. Given the nature of the content (announcing positive external validation/publication), RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for non-standard corporate news releases that aren't earnings or management changes.
2017-03-02 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is titled "MAUNA KEA TECHNOLOGIES ANNONCE LA MISE EN PLACE D'UN FINANCEMENT PAR EMPRUNT OBLIGATAIRE DE 7 M€" (Mauna Kea Technologies announces the establishment of a €7M bond financing). The content details the securing of €7.0 million in non-dilutive financing through two tranches of bonds from IPF Partners. This clearly relates to the company's fundraising and capital structure activities. Based on the provided definitions, the most appropriate category is 'Capital/Financing Update' (CAP). The document is a formal announcement detailing the terms of the debt issuance.
2017-02-08 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.